Cutting Balloon Versus Conventional Balloon Angioplasty for the Treatment of Coronary Artery Disease

Size: px
Start display at page:

Download "Cutting Balloon Versus Conventional Balloon Angioplasty for the Treatment of Coronary Artery Disease"

Transcription

1 Cutting Balloon Versus Conventional Balloon Angioplasty for the Treatment of Coronary Artery Disease a report by Dr Remo Albiero Director, Cardiac Catheterisation Laboratory, Clinica San Rocco, Brescia Dr Remo Albiero is Director of the Cardiac Catheterisation Laboratory at the Clinica San Rocco (Gruppo San Donato) in Brescia, Italy. He was previously Senior Associate of the Catheterisation Laboratory at EMO Centro Cuore Columbus in Milan, Italy. Since 1989 he has had 124 abstracts presented at the American College of Cardiology (ACC)/European Society of Cardiology (ESC)/American Heart Association (AHA) congresses 21 as first author. He also has 68 English language publications, with 2 of these as first author. He has been co-author on numerous journal articles. Dr Albiero graduated in medicine and surgery from the University of Verona in 1987, and a obtained diploma in cardiology from the same university in The cutting balloon (CB) 1 is a special balloon catheter with three or four atherotomes (microsurgical blades) bonded longitudinally to its surface, suitable for creating discrete longitudinal incisions in the atherosclerotic target coronary segment during balloon inflation. With the cutting balloon, the increase in the vessel lumen diameter is obtained in a more controlled fashion and with a lower balloon inflation pressure than conventional percutaneous transluminal coronary angioplasty () this controlled dilatation could reduce the extent of vessel wall injury and the incidence of restenosis. The Global trial, 2 a multicentre, randomised trial on 1,238 patients, tested the hypothesis that surgical dilatation using the CB (617 patients) could result in less arterial trauma, fewer dissections and less frequent restenosis than conventional (621 patients). The lesion selected in this study (simple type A/B1 lesions) were treated by a single cutting balloon inflation, with a balloon artery ratio of 1.1:1. The controlled dilatation of the cutting balloon did not reduce the rate of angiographic restenosis compared with conventional (CB 31.4%, compared with 3.4%, p=.75). Five coronary perforations occurred only in the CB arm (.8% compared with %, p=.3). The results of the Global trial indicate that CB angioplasty in simple lesions is not superior to conventional for the prevention of restenosis and should probably be reserved for more complex lesions in which the controlled dilatation of the CB could provide better acute and mid-term results compared with conventional. In fact, this device is mainly used to treat in-stent restenosis (ISR), ostial lesions, bifurcation lesions and smaller vessels and to expand resistant fibrocalcified plaques not dilated by high pressure conventional balloons. subgroup of patients with diffuse and/or severe ISR. 3,5,7 1 Numerous small retrospective studies have shown the benefits of the CB for the prevention of the recurrence of ISR compared with conventional. 11,12 These studies were followed by small pilot randomised studies that also showed a clinical benefit associated with the use of a CB. 13 The author s prior observation 14 demonstrated a greater capacity of cutting balloon angioplasty (CBA) to extrude a fibrous residual neo-intimal plaque out of the stent struts than conventional. The microblades of the cutting balloon were able to surgically incise the restenotic plaques up to the metallic stent cage these incisions probably facilitated the maximum extrusion of the neo-intimal plaque. This hypothesis was confirmed by an intravascular ultrasound (IVUS) study 11 that showed a larger luminal area acute gain after CBA (2.5 ±.8mm 2 ) than after conventional (1.8 ± 1.mm 2 ), which translated into a lower restenosis rate at 5.4-month follow-up (CBA 24%; 59%). Two large prospective, randomised, multicentre studies both failed to demonstrate an advantage of the CB over for the treatment of ISR: the Restenosis Cutting Balloon Evaluation Trial (RESCUT); and the Restenosis Reduction by Cutting Balloon Evaluation (REDUCE) II trial. The RESCUT trial 15 is a European study designed to assess the results of CB (n = 214) compared with conventional (n = 214) for the treatment of ISR. The study included lesions shorter than 25mm in native coronary arteries with all types of ISR patterns (focal, multifocal, diffuse and proliferative). 48 In-stent Restenosis With the rapid explosion in stent use, ISR has become a significant clinical problem. 3 Re-dilatation using a conventional balloon has been the most commonly used approach to treat ISR, 4 7 but with a high recurrent restenosis rate, especially in the This large multicentre randomised study differed from previous reports in that the rates of clinical events (death, myocardial infarction (MI) and target lesion revascularisation (TLR)) were similar between the two groups (see Figure 1), as well as the rates of restenosis and its patterns (see Figure 2 and 3).

2 albiero_papextended.qxp 14/4/5 12:43 pm Page 49 Cutting Balloon Versus Conventional Balloon Angioplasty for the Treatment of CAD The CB demonstrated some practical advantages over conventional : revascularisation compared with conventional angioplasty (1.2% compared with 16.6%; p=.4).16 balloon slippage was less frequent in the CB group (6.5% compared with 25%, p<.1); and The use of CBs could not translate into clinical or angiographic benefits for patients with ISR treated with drug-eluting stents (DES), as a result of the procedural differences in the treatment of ISR using adjunctive brachytherapy compared with restenting using a DES. In the first case (before adjunctive brachytherapy), it is recommended to optimally treat ISR by conventional/cba or atherectomy, avoiding additional stenting to reduce the risk of late stent thrombosis. In the case of restenting with a DES, an optimal balloon pre-treatment of ISR is not necessary, nor is the use of a CB to avoid balloon slippage, because the operator can reduce the risk of vessel injury at the stent edges, even in the event of balloon slippage, by simply predilating the ISR lesion using an undersized non-compliant conventional balloon. there was a trend towards a lower need for additional stenting (CB 3.9% compared with 8.%, p=.7), mainly due to a lower frequency of residual stenosis more than 3% and type D F dissections. These advantages could be explained as follows: conventional balloons, particularly short balloons when positioned within in-stent restenotic lesions, tend to move forwards or backwards during inflation into larger segments with lower resistance, because the hyperplastic tissue has a smooth slippery surface. With a CB this problem is prevented by the blades, which anchor the balloon to the plaque during balloon inflation, reducing the risk of dissection at the stent margins. This fact could be important when there is the need to carefully control the boundaries of the injured segment, for example before coronary brachytherapy, as demonstrated in the Registry Novoste (RENO) where pre-treatment with CB before brachytherapy (performed using beta radiation) significantly reduced six-month target-vessel The second randomised multicentre trial to be discussed is the Japanese REDUCE II trial on 416 patients. The six-month result of this study (not yet published at the time of press) were not different between the two groups binary restenosis was 24% in the CB group compared with 22% in the arm and TLR was 2% in both arms.

3 Figure 1: RESCUT Cumulative MACE 2 1 Figure 2: RESCUT Restenosis at Seven-month Follow-up 35 p=ns Death MI TLR p= compared with CB angioplasty and conventional. A total of 263 patients with a lesion in a small vessel (reference diameters less than 3mm) were randomly assigned to undergo GPBA (n=85), CBA (n=88), or conventional (n=9). The cumulative inflation time was more than 1 minutes in GPBA. Compared with conventional, GPBA resulted in a lower final residual diameter stenosis (27.3% compared with 34.2%, p=.1) and decreased the need for stent placement (8.% compared with 22.2%, p=.31). At follow-up, the restenosis rates were lower with GPBA (31.3%, p=.34) and CBA (32.9%, p=.59) than conventional (5.6%). Target lesion revascularisation was less frequently needed with GPBA (2.5%, p=.43) and CBA (2.%, p=.33) than conventional plain old balloon angioplasty (POBA) (37.6%) Restenosis Figure 3: RESCUT Patterns of Restenosis Another retrospective study in small coronary arteries evaluated the clinical and angiographic benefits of stenting compared with CB angioplasty and conventional. A total of 327 lesions in small vessels (reference diameters less than 2.5mm by quantitative coronary angiography (QCA)) were analysed stenting (n=11), CB (n=87) and conventional (n=13). Angiographic restenosis was encountered in 43.9% of the stent, 31% of the CB and 46.5% of the conventional groups (p =.48) p=ns Major adverse coronary events (MACE; death, MI and TLR) at follow-up were significantly lower in the CB compared with other groups (CB, 2.3%; conventional, 37.3%; stent, 33.3%; p=.36). In conclusion, in small vessels less than 2.5mm, the CB procedure provided superior angiographic and clinical outcomes to stenting or conventional. 19 Focal <1mm Ostial or Bifurcation Lesions The CB may provide an advantage over conventional in complex lesions such as ostial or bifurcation lesions; however, a large retrospective study of 1,58 patients did not show a lower TLR in patients treated with the CB compared with conventional in ostial or bifurcation lesions. 17 Small Vessels Diffuse >1mm Before Stenting By favourably scoring the plaque prior to stent implantation, CBA may be preferable (compared with a conventional balloon) before stent placement. This hypothesis was evaluated in the REDUCE III study, a Japanese prospective, randomised multicentre trial on 52 patients. At six-month follow-up, restenosis rate was significantly lower in the CB group compared with conventional (1.7% compared with 17.1%, respectively, p=.58). Table 1 summarises the possible indications for use of the CB, instead of a conventional balloon, before implanting a DES. 5 Small vessel size represents a critical risk factor for an adverse outcome after both conventional and stenting. A recent study in small coronary arteries evaluated the clinical and angiographic benefits of gradual and prolonged balloon angioplasty (GPBA) using a perfusion balloon, to cause less arterial trauma, CB Complications and Drawbacks A trend for higher complication rates have been reported with the use of CB, including vessel perforation when using oversized balloons or when the CB is used outside the stent, 2,21 dissection, 22,23

4 Cutting Balloon Versus Conventional Balloon Angioplasty for the Treatment of CAD spasm and entrapment. 24 The co-existence of many, rather than a single, anatomical and procedural characteristics may increase the risk of vascular complications following CB angioplasty. The lesion eccentricity is probably the most important factor, followed by vessel calcification and a large balloon artery ratio. The appearance, at angiography, of an overdilated vessel after CBA should raise suspicion of an excessively deep cut of the device. 23 Finally, the cost of the CB is higher (US$1, compared with US$25 for conventional balloon). Conclusions Based on the available data, the CB can be used: to treat in-stent restenosis, due to some procedural advantages over conventional the microblades (atherotomes) prevent balloon slippage (melon-seeding), reducing the injury zone and edge dissection; to treat small vessels, although a gradual and prolonged CBA using a perfusion balloon could be equally effective in reducing restenosis; based on anecdotal data, to reduce plaque shift in ostial/bifurcation lesions; based on anecdotal data, to treat resistant Table1: Reasons to Use the Cutting Balloon Before Implantation of a DES Type of lesion Reason to use cutting balloon In-stent restenosis (ISR) Conventional balloon slips causing injury distally. CB scores the intimal hyperplasia which favours plaque extrusion through original stent struts, maximising lumen area before DES placement. Small vessel CB compressed the plaque, creating a larger lumen area for stent placement. Bifurcation CB reduces plaque shift, while direct stenting and POBA cause it. In highly fibrotic lesions, CB severs the fibrotic strands. In focal lesions, the 6mm long CB controls the injury zone. Ostial CB reduce plaque shift, while direct stenting and (side branch and aorta) POBA cause it. In highly fibrotic lesions, CB severs the fibrotic strands. In focal lesions, the 6mm long CB controls the injury zone. Resistant POBA and stenting do not resolve the stenosis. (hard plaque and calcium) Easier to use than rotational atherectomy. lesions, although rotational atherectomy is preferred (CB is difficult to deliver in moderate to severe calcified lesions); and before stenting using a bare-metal stent (REDUCE III). New Vascular Horizons PEOPLE. IDEAS. PASSION. Stroke Management Emboli Management Peripheral Intervention PRIMUS Peripheral Embolisation THE ENDOVASCULAR COMPANY TM

5 References 1. Barath P, Fishbein M C, Vari S et al., : a novel approach to percutaneous angioplasty, Am. J. Cardiol. (1 November 1991);68(11): pp. 1,249 1, Mauri L, Bonan R, Weiner B H et al., angioplasty for the prevention of restenosis: results of the Cutting Balloon Global Randomized Trial, Am. J. Cardiol. (15 November 22);9(1): pp. 1,79 1, Mintz G S, Hoffmann R, Mehran R et al., In-stent restenosis: the Washington Hospital Center experience, Am. J. Cardiol. (9 April 1998);81(7A):7E 13E. 4. Baim D S, Levine M J, Leon M B et al., Management of restenosis within the Palmaz-Schatz coronary stent (the U.S. multicenter experience. The U.S. Palmaz-Schatz Stent Investigators, Am. J. Cardiol. (1 February 1993);71(4): pp Bauters C, Banos J L, Van Belle E et al., Six-month angiographic outcome after successful repeat percutaneous intervention for in-stent restenosis, Circulation (3 February 1998);97(4): pp Reimers B, Moussa I, Akiyama T et al., Long-term clinical follow-up after successful repeat percutaneous intervention for stent restenosis, J. Am. Coll. Cardiol. (July 1997);3(1): pp Bossi I, Klersy C, Black A J et al., In-stent restenosis: long-term outcome and predictors of subsequent target lesion revascularization after repeat balloon angioplasty, J. Am. Coll. Cardiol. (May 2);35(6): pp. 1,569 1, Mehran R, Dangas G, Abizaid A S et al., Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome, Circulation (2 November 1999);1(18): pp. 1,872 1, Kini A, Marmur J D, Dangas G et al., Angiographic patterns of in-stent restenosis and implications on subsequent revascularization, Catheter Cardiovasc. Interv. (Jan 2);49(1): pp Eltchaninoff H, Koning R, Tron C et al., Balloon angioplasty for the treatment of coronary in-stent restenosis: immediate results and 6-month angiographic recurrent restenosis rate, J. Am. Coll. Cardiol. (October 1998);32(4): pp Muramatsu T, Tsukahara R, Ho M et al., Efficacy of cutting balloon angioplasty for in-stent restenosis: an intravascular ultrasound evaluation, J. Invasive Cardiol. (June 21);13(6): pp Adamian M, Colombo A, Briguori C et al., angioplasty for the treatment of in-stent restenosis: a matched comparison with rotational atherectomy, additional stent implantation and balloon angioplasty, J. Am. Coll. Cardiol. (September 21);38(3): pp Montorsi P, Galli S, Fabbiocchi F et al., Randomized trial of conventional balloon angioplasty versus cutting balloon for in-stent restenosis. Acute and 24-hour angiographic and intravascular ultrasound changes and long-term follow-up, Ital. Heart J. (April 24);5(4): pp Albiero R, Nishida T, Karvouni E et al., angioplasty for the treatment of in-stent restenosis, Catheter Cardiovasc. Interv. (August 2);5(4): pp Albiero R, Silber S, Di Mario C et al., versus conventional balloon angioplasty for the treatment of instent restenosis: results of the restenosis cutting balloon evaluation trial (RESCUT), J. Am. Coll. Cardiol. (17 March 24);43(6): pp Roguelov C, Eeckhout E, De Benedetti E et al., Clinical outcome following combination of cutting balloon angioplasty and coronary beta-radiation for in-stent restenosis: a report from the RENO registry, J. Invasive Cardiol. (December 23);15(12): pp Bair et al., J. Am. Coll. Cardiol. (23);41:5A 18. Umeda H, Iwase M, Kanda H et al., Promising efficacy of primary gradual and prolonged balloon angioplasty in small coronary arteries: a randomized comparison with cutting balloon angioplasty and conventional balloon angioplasty, Am. Heart J. (January 24);147(1):E Iijima R, Ikari Y, Wada M et al., angioplasty is superior to balloon angioplasty or stent implantation for small coronary artery disease, Coron. Artery Dis. (November 24);15(7): pp Ako J, Honda Y, Fitzgerald P J, Impending coronary perforation after cutting balloon angioplasty, Heart (January 25);91(1):e Quan V H, Stone J R, Couper G S et al., Coronary artery perforation by cutting balloon resulting in dissecting subepicardial hematoma and avulsion of the vasculature, Catheter Cardiovasc. Interv. (February 25);64(2): pp Haridas K K, Vijayakumar M, Viveka K et al., Fracture of cutting balloon microsurgical blade inside coronary artery during angioplasty of tough restenotic lesion: a case report, Catheter Cardiovasc. Interv. (February 23);58(2): pp Montorsi P, Galli S, Fabbiocchi F et al., Different types of coronary artery wall injury following cutting balloon angioplasty, Ital. Heart J. (November 22);3(11): pp Guven H, Thanigaraj S, Beardslee M, Noninvasive evaluation of a cutting balloon entrapped in a left main coronary artery using transesophageal echocardiography, Echocardiography (February 25);22(2): pp

Rotational Atherectomy for the Treatment of In-Stent Restenosis

Rotational Atherectomy for the Treatment of In-Stent Restenosis Home SVCC Area: English - Español - Português Rotational Atherectomy for the Treatment of In-Stent Restenosis Steven L. Goldberg, MD Cardiac Catheterization Laboratory, University of Washington Medical

More information

Clinical Research Intracoronary Stenting with Crushing in Coronary Artery Bifurcation Lesions: Initial Results and Medium-Term Follow Up

Clinical Research Intracoronary Stenting with Crushing in Coronary Artery Bifurcation Lesions: Initial Results and Medium-Term Follow Up Hellenic J Cardiol 45: 379-383, 2004 Clinical Research Intracoronary Stenting with Crushing in Coronary Artery Bifurcation Lesions: Initial Results and Medium-Term Follow Up PETROS S. DARDAS, DIMITRIS

More information

Evolu'on of Balloon Angioplasty From POBA to newer technologies NCVH May 26, 2015

Evolu'on of Balloon Angioplasty From POBA to newer technologies NCVH May 26, 2015 Evolu'on of Balloon Angioplasty From POBA to newer technologies NCVH May 26, 2015 Cezar Staniloae, MD Heart and Vascular Ins7tute New York University Medical Center Overview 1. Physics of balloon angioplasty

More information

ORIGINAL ARTICLES: Morphology and Location of Restenosis Following Bare Metal Coronary Stenting

ORIGINAL ARTICLES: Morphology and Location of Restenosis Following Bare Metal Coronary Stenting Page 1 / 7 ORIGINAL ARTICLES: Morphology and Location of Restenosis Following Bare Metal Coronary Stenting - Marc J. Schweiger, MD, Ehsan Ansari, MD, Gregory R. Giugliano, MD, *James Mathew, MD, Ashequl

More information

Review of Intracoronary Radiation for In-Stent Restenosis

Review of Intracoronary Radiation for In-Stent Restenosis Review of Intracoronary Radiation for In-Stent Restenosis Robert Lew, MBBS, FRACP, Andrew Ajani, MD, Ron Waksman, MD, FACC Vascular Brachytherapy using beta and gamma radiation is the standard care for

More information

European Heart Journal (1999) 20, 1014 1019 Article No. euhj.1998.1395, available online at http://www.idealibrary.com on

European Heart Journal (1999) 20, 1014 1019 Article No. euhj.1998.1395, available online at http://www.idealibrary.com on European Heart Journal (1999) 20, 1014 1019 Article No. euhj.1998.1395, available online at http://www.idealibrary.com on Working Group Report Indications for intracoronary stent placement: the European

More information

Ostial LAD: Single stent approach is the best. Antonio A. Pocoví, MD, FSCAI, MTSAC, Advisory Council Member, CACI

Ostial LAD: Single stent approach is the best. Antonio A. Pocoví, MD, FSCAI, MTSAC, Advisory Council Member, CACI Ostial LAD: Single stent approach is the best Antonio A. Pocoví, MD, FSCAI, MTSAC, Advisory Council Member, CACI Chair, Interventional Cardiology Sanatorio San Lucas Instituto Alexander Fleming Buenos

More information

MEDICAL POLICY No. 91580-R1 DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE

MEDICAL POLICY No. 91580-R1 DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE Effective Date: October 1, 2015 Review Dates: 10/11, 10/12, 10/13, 8/14, 8/15 Date Of Origin: October 12, 2011 Status: Current Summary of Changes Clarifications:

More information

GUIDELINES ON MEDICAL DEVICES EVALUATION OF CLINICAL DATA - A GUIDE FOR MANUFACTURERS AND NOTIFIED BODIES -

GUIDELINES ON MEDICAL DEVICES EVALUATION OF CLINICAL DATA - A GUIDE FOR MANUFACTURERS AND NOTIFIED BODIES - EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Cosmetics and Medical Devices MEDDEV 2.7.1 Appendix 1 December 2008 GUIDELINES ON MEDICAL DEVICES EVALUATION OF CLINICAL DATA

More information

Coronary Bifurcation Treatment: Update from the European Bifurcation Club. Remo Albiero, MD Ist. Clinico S. Rocco Brescia (Italy)

Coronary Bifurcation Treatment: Update from the European Bifurcation Club. Remo Albiero, MD Ist. Clinico S. Rocco Brescia (Italy) Coronary Bifurcation Treatment: Update from the European Bifurcation Club Remo Albiero, MD Ist. Clinico S. Rocco Brescia (Italy) Disclosure Statement of Financial Interest Within the past 12 months, I

More information

Drug-Eluting Balloons. Klaus Bonaventura Department of Cardiology and Angiology Heart Thorax Vascular Center, Klinikum Ernst von Bergmann, Potsdam

Drug-Eluting Balloons. Klaus Bonaventura Department of Cardiology and Angiology Heart Thorax Vascular Center, Klinikum Ernst von Bergmann, Potsdam Drug-Eluting Balloons Klaus Bonaventura Department of Cardiology and Angiology Heart Thorax Vascular Center, Klinikum Ernst von Bergmann, Potsdam Potential conflicts of interest Speaker s name: Klaus Bonaventura

More information

The Bioresorbable Vascular Stent Dr Albert Ko

The Bioresorbable Vascular Stent Dr Albert Ko The Bioresorbable Vascular Stent Dr Albert Ko Dr Albert Ko MB BS, FRACP, FCSANZ Interventional/General Cardiologist Ascot Cardiology Symposium 2013 Treatment Goals for Coronary Artery Disease Relieve of

More information

The Pantera Lux Paclitaxel DEB Device Description and Clinical Studies. Christoph Hehrlein, University Clinic Freiburg i.br.

The Pantera Lux Paclitaxel DEB Device Description and Clinical Studies. Christoph Hehrlein, University Clinic Freiburg i.br. The Pantera Lux Paclitaxel DEB Device Description and Clinical Studies Christoph Hehrlein, University Clinic Freiburg i.br. Germany Disclosure Statement of Financial Interest Within the past 12 months,

More information

NOVOSTE BETA-CATH SYSTEM

NOVOSTE BETA-CATH SYSTEM HOSPITAL INPATIENT AND OUTPATIENT BILLING GUIDE FOR THE NOVOSTE BETA-CATH SYSTEM INTRAVASCULAR BRACHYTHERAPY DEVICE This guide is intended solely for use as a tool to help hospital billing staff resolve

More information

A Post-market Study to Assess the STENTYS Self-exPanding COronary Stent In AcuTe myocardial InfarctiON in Real Life APPOSITION III

A Post-market Study to Assess the STENTYS Self-exPanding COronary Stent In AcuTe myocardial InfarctiON in Real Life APPOSITION III A Post-market Study to Assess the STENTYS Self-exPanding COronary Stent In AcuTe myocardial InfarctiON in Real Life APPOSITION III Gilles Montalescot, MD, PhD Pitié-Salpêtrière Hospital, Paris, France

More information

Majestic Trial 12 Month Results

Majestic Trial 12 Month Results Majestic Trial 12 Month Results S.Müller-Hülsbeck, MD, EBIR, FCIRSE, FICA ACADEMIC HOSPITALS Flensburg of Kiel University Ev.-Luth. Diakonissenanstalt zu Flensburg Knuthstraße 1, 24939 FLENSBURG Dept.

More information

Duration of Dual Antiplatelet Therapy After Coronary Stenting

Duration of Dual Antiplatelet Therapy After Coronary Stenting Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are

More information

Editorial. Adult Cardiology - Meta-analysis

Editorial. Adult Cardiology - Meta-analysis Editorial Adult Cardiology - Meta-analysis Simple Versus Complex Bifurcation Stenting Strategies A Meta Analysis of Randomized Controlled Trials in the Drug Eluting Stent Era Ana Beatriz R. Medrano, MD

More information

OCT ASSESSMENT OF CUTTING BALLOON ANGIOPLASTY FOR IN-STENT RESTENOSIS

OCT ASSESSMENT OF CUTTING BALLOON ANGIOPLASTY FOR IN-STENT RESTENOSIS OCT ASSESSMENT OF CUTTING BALLOON ANGIOPLASTY FOR IN-STENT RESTENOSIS Division of Cardiology, Mount Sinai Hospital, New York, NY, USA Yuliya Vengrenyuk, PhD; and Annapoorna Kini, MD OCT ASSESSMENT OF CUTTING

More information

Status of Drug-Eluting Coronary Stents

Status of Drug-Eluting Coronary Stents Status of Drug-Eluting Coronary Stents EVOLUTION OF PERCUTANEOUS CORONARY INTERVENTIONAL TECHNOLOGIES The introduction of percutaneous transluminal coronary angioplasty (PTCA) in the late1970s provided

More information

California Health and Safety Code, Section 1256.01

California Health and Safety Code, Section 1256.01 California Health and Safety Code, Section 1256.01 1256.01. (a) The Elective Percutaneous Coronary Intervention (PCI) Pilot Program is hereby established in the department. The purpose of the pilot program

More information

Intracoronary Stenting and. Robert A. Byrne, Julinda Mehilli, Salvatore Cassese, Franz-Josef Neumann, Susanne Pinieck, Tomohisa Tada,

Intracoronary Stenting and. Robert A. Byrne, Julinda Mehilli, Salvatore Cassese, Franz-Josef Neumann, Susanne Pinieck, Tomohisa Tada, Prospective, Randomized Trial of Paclitaxel-Eluting Balloon versus Paclitaxel-Eluting Stent versus Balloon Angioplasty for Treatment of Coronary Restenosis in Limus- Eluting Stents Intracoronary Stenting

More information

Imaging of Thoracic Endovascular Stent-Grafts

Imaging of Thoracic Endovascular Stent-Grafts Imaging of Thoracic Endovascular Stent-Grafts Tariq Hameed, M.D. Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, Indiana Disclosures: No relevant financial

More information

Is Stenting or Coronary Artery By-pass Grafting the Better Treatment for This Patient?

Is Stenting or Coronary Artery By-pass Grafting the Better Treatment for This Patient? Is Stenting or Coronary Artery By-pass Grafting the Better Treatment for This Patient? --- NIRS-IVUS TVC Imaging Adds Additional Information for the Heart Team Dr. Luis Tami Memorial Regional Hospital

More information

Experience of Direct Coronary Stenting at National Institute of Cardiovascular Diseases

Experience of Direct Coronary Stenting at National Institute of Cardiovascular Diseases Experience of Direct Coronary Stenting at National Institute of Cardiovascular Diseases T. Masood,T. Sagheer,D. Jan,N. Qamar,A.M.A. Faruqui ( National Institute of Cardiovascular Diseases (NICVD), Karachi.

More information

Cilostazol versus Clopidogrel after Coronary Stenting

Cilostazol versus Clopidogrel after Coronary Stenting Cilostazol versus Clopidogrel after Coronary Stenting Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine Seoul, Korea AMC, 2004 Background

More information

Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty

Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty Round Table: Antithrombotic therapy beyond ACS Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty M. Matsagkas, MD, PhD, EBSQ-Vasc Associate Professor

More information

STONY BROOK UNIVERSITY HOSPITAL VASCULAR CENTER CREDENTIALING POLICY

STONY BROOK UNIVERSITY HOSPITAL VASCULAR CENTER CREDENTIALING POLICY STONY BROOK UNIVERSITY HOSPITAL VASCULAR CENTER CREDENTIALING POLICY Per Medical Board decision March 18, 2008: These credentialing standards do NOT apply to peripheral angiography performed in the context

More information

Copenhagen University Hospital Rigshospitalet Aarhus University Hospital Skejby Denmark

Copenhagen University Hospital Rigshospitalet Aarhus University Hospital Skejby Denmark Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-elevation myocardial infarction 3 year follow-up of the randomised trial Peter Clemmensen, Henning Kelbæk,

More information

PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators

PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease PRECOMBAT Trial Seung-Whan Lee, MD, PhD On behalf

More information

The Minvasys Amazonia Pax & Nile Pax Polymer Free Paclitaxel Eluting Stent Program

The Minvasys Amazonia Pax & Nile Pax Polymer Free Paclitaxel Eluting Stent Program The Minvasys Amazonia Pax & Nile Pax Polymer Free Paclitaxel Eluting Stent Program Jean Fajadet, MD, FESC Clinique Pasteur - Toulouse - France Disclosure statement Nothing to disclose Dedicated Delivery

More information

SAMPLE. Asia-Pacific Interventional Cardiology Procedures Outlook to 2020. Reference Code: GDMECR0061PDB. Publication Date: May 2014

SAMPLE. Asia-Pacific Interventional Cardiology Procedures Outlook to 2020. Reference Code: GDMECR0061PDB. Publication Date: May 2014 Asia-Pacific Interventional Cardiology Procedures Outlook to 2020 Reference Code: GDMECR0061PDB Publication Date: May 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2

More information

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,

More information

AND SYLLABUS FOR INTERVENTIONAL CARDIOLOGY SUBSPECIALITY TRAINING IN EUROPE

AND SYLLABUS FOR INTERVENTIONAL CARDIOLOGY SUBSPECIALITY TRAINING IN EUROPE CURRICULUM AND SYLLABUS FOR INTERVENTIONAL CARDIOLOGY SUBSPECIALITY TRAINING IN EUROPE Document prepared by: Carlo Di Mario, FESC Germano Di Sciascio, FESC Jean-Luc Dubois-Rande,FESC Rolf Michels, FESC

More information

CORONARY ARTERY BYPASS GRAFTS, STENTS, AND EXTRACORONARY CARDIAC DZ. Charles White MD

CORONARY ARTERY BYPASS GRAFTS, STENTS, AND EXTRACORONARY CARDIAC DZ. Charles White MD CORONARY ARTERY BYPASS GRAFTS, STENTS, AND EXTRACORONARY CARDIAC DZ Charles White MD Director of Thoracic Imaging Department of Radiology University of Maryland CORONARY ARTERY BYPASS GRAFTS First performed

More information

SeQuent Please balloon catheter for in-stent coronary restenosis. NICE medical technology guidance 1. Issue date: December 2010

SeQuent Please balloon catheter for in-stent coronary restenosis. NICE medical technology guidance 1. Issue date: December 2010 Issue date: December 2010 SeQuent Please balloon catheter for in-stent coronary restenosis NICE medical technology guidance 1 1 NICE medical technology guidance 1 NICE medical technology guidance 1 SeQuent

More information

INTRODUCTION. Key Words:

INTRODUCTION. Key Words: Case Report Acta Cardiol Sin 2014;30:485 489 Successful Revascularization of Chronic Total Occlusion in Native Coronary Arteries through an Occluded Saphenous Bypass Vein Graft: A Retrograde Alternative

More information

LEADERS: 5-Year Follow-up

LEADERS: 5-Year Follow-up LEADERS: -Year Follow-up from a Prospective, Randomized Trial of Biolimus A9-eluting Stents with a Biodegradable Polymer vs. Sirolimus-eluting Stents with a Durable Polymer : Final Report of the LEADERS

More information

PATIENT INFORMATION BOOKLET

PATIENT INFORMATION BOOKLET PATIENT INFORMATION BOOKLET Wingspan Stent System with Gateway PTA Balloon Catheter TABLE OF CONTENTS Definitions... 2 What is the Purpose of This Booklet?... 3 What is an Intracranial Lesion?... 3 Who

More information

Early And Late Outcome For Single Versus Double Stenting For Bifurcational Coronary Artery Lesions

Early And Late Outcome For Single Versus Double Stenting For Bifurcational Coronary Artery Lesions ORIGINAL CONTRBUTION / CLINICAL INVESTIGATION Early And Late Outcome For Single Versus Double Stenting For Bifurcational Coronary Artery Lesions Aram J. Mirza Correspondence: Dr. Aram J.Mirza Interventional

More information

INTERVENTION IN OSTIAL CORONARY LESIONS:

INTERVENTION IN OSTIAL CORONARY LESIONS: INTERVENTION IN OSTIAL CORONARY LESIONS: Antony (92), le 18 septembre 2013 JEAN MARC PERNES Hopital Privé Antony FRANCE Perfection of Precise Ostial Stent Placement Ostial lesions, including aorta ostial

More information

Clinical Programs. Medtronic Coronary Stent Systems. driver BMS

Clinical Programs. Medtronic Coronary Stent Systems. driver BMS Clinical Programs Medtronic Coronary Stent Systems Endeavor DES driver BMS July 2010 Contents Overview of Clinical Programs... 2 Drug-Eluting Stents ENDEAVOR I*... 4 ENDEAVOR II*... 6 ENDEAVOR II Continued

More information

Antonio Colombo MD on behalf of the SECURITY Investigators

Antonio Colombo MD on behalf of the SECURITY Investigators Second Generation Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy - The SECURITY Randomized Clinical Trial Antonio Colombo MD on behalf of the SECURITY

More information

Fundación Favaloro. Fundación Favaloro

Fundación Favaloro. Fundación Favaloro Superficial Femoral Artery: Which h Factors Influence Patency? Oscar A. Mendiz.MD.FACC.FSCAI Chairman hi of Interventional Cardiology dil March 2010 Name: Oscar A. Mendiz Disclosure I have the following

More information

Perioperative Cardiac Evaluation

Perioperative Cardiac Evaluation Perioperative Cardiac Evaluation Caroline McKillop Advisor: Dr. Tam Psenka 10-3-2007 Importance of Cardiac Guidelines -Used multiple times every day -Patient Safety -Part of Surgical Care Improvement Project

More information

Coronary Stents. What is a Coronary Artery stent?

Coronary Stents. What is a Coronary Artery stent? What is a Coronary Artery stent? Coronary Stents A coronary stent is stainless tube with slots. It is mounted on a balloon catheter in a "crimped" or collapsed state. When the balloon of is inflated, the

More information

Angioplasty and Stent Education Guide

Angioplasty and Stent Education Guide Angioplasty and Stent Education Guide Table of Contents Treating coronary artery disease...2 What is coronary artery disease...3 Coronary artery disease treatment options...4 What are coronary artery

More information

Polymer-Based, Paclitaxel-Eluting TAXUS Liberté Stent in De Novo Lesions: The Pivotal TAXUS ATLAS Trial

Polymer-Based, Paclitaxel-Eluting TAXUS Liberté Stent in De Novo Lesions: The Pivotal TAXUS ATLAS Trial Polymer-Based, Paclitaxel-Eluting Stent in De Novo Lesions: The Pivotal TAXUS ATLAS Trial Mark A. Turco, John A. Ormiston, Jeffrey J. Popma, Lazar Mandinov, Charles D. O'Shaughnessy, Tift Mann, Thomas

More information

Repeat Coronary Revascularization Procedures after Successful Bare-Metal or Drug-Eluting Stent Implantation

Repeat Coronary Revascularization Procedures after Successful Bare-Metal or Drug-Eluting Stent Implantation Original Contribution Repeat Coronary Revascularization Procedures after Successful Bare-Metal or Drug-Eluting Stent Implantation Cynthia A. Yock, MS, J. Michael Isbill, MS, Spencer B. King III, MD, Mark

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT European Medicines Agency London, 22 March 2007 Doc. Ref. EMEA/CHMP/EWP/110540/2007 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON THE DEVELOPMENT OF MEDICINAL SUBSTANCES CONTAINED

More information

ESC PCI Guidelines: / Sigmund Silber et al. 1

ESC PCI Guidelines: / Sigmund Silber et al. 1 For the first time! ESC PCI Guidelines: / Sigmund Silber et al. 1 in 2002: 649.332 in 2002: 541.964 ESC PCI Guidelines: Introduction and Definitions / Sigmund Silber et al. 2 ESC PCI Guidelines: Introduction

More information

TAXUS Express 2. Paclitaxel-Eluting Coronary Stent System. Patient Information Guide

TAXUS Express 2. Paclitaxel-Eluting Coronary Stent System. Patient Information Guide TAXUS Express 2 Paclitaxel-Eluting Coronary Stent System Patient Information Guide 1 Table of Contents Coronary Artery Disease...2 Who Is at Risk?...3 Diagnosis of Coronary Artery Disease...3 Treatment

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31,

More information

European Cardiology. Volume 6 Issue 4 Extract. Svelte Acrobat Stent-On- A-Wire Coronary Stent System. J Ribamar Costa Jr and Alexandre Abizaid

European Cardiology. Volume 6 Issue 4 Extract. Svelte Acrobat Stent-On- A-Wire Coronary Stent System. J Ribamar Costa Jr and Alexandre Abizaid European Cardiology Volume 6 Issue 4 Extract Svelte Acrobat Stent-On- A-Wire Coronary Stent System J Ribamar Costa Jr and Alexandre Abizaid Instituto Dante Pazzanese de Cardiologia, São Paulo www.touchcardiology.com

More information

Medical publications - Open Vs Closed Cell Stents

Medical publications - Open Vs Closed Cell Stents Designing the Ideal Stent Stent cell geometry and its clinical significance in carotid stenting. BY MARK H. WHOLEY, MD, AND ENDER A. FINOL, PHD Balloon-expandable closed-cell stents were introduced for

More information

έΰζβν αππ έκυ,νσϊίία κν1γν πλδζέκυνβί1γ π ηία δεόμνκαλ δκζόΰκμ, θν δ υγυθ άμνγνκαλ /εάμ ΚζδθδεάμΝ υλωεζδθδεάμν

έΰζβν αππ έκυ,νσϊίία κν1γν πλδζέκυνβί1γ π ηία δεόμνκαλ δκζόΰκμ, θν δ υγυθ άμνγνκαλ /εάμ ΚζδθδεάμΝ υλωεζδθδεάμν ΝΠθ ζζάθδκνσθϋ λδκν έΰκ μνεδν ιωθκ κεκη δεάμνι λδεάμ έΰζβν έκ,νσϊίί κν1γν λδζέκνβί1γ Α Α φ ; έζ δκμννένσθόμ ηί δεόμνκλ δκζόΰκμ, θν δ γθ άμνγνκλ /εάμ ΚζδθδεάμΝ λωεζδθδεάμν ένivus Scientific Director, Mediolanum

More information

Popliteal artery: to stent or not to stent?

Popliteal artery: to stent or not to stent? Popliteal artery: to stent or not to stent? Karl-Ludwig Schulte Vascular Center Berlin Ev. Hospital Königin Elisabeth St. Gertrauden Hospital University Hospital Charité, CC11 Humboldt-University Berlin

More information

Renovascular Hypertension

Renovascular Hypertension Renovascular Hypertension Philip Stockwell, MD Assistant Professor of Medicine (Clinical) Warren Alpert School of Medicine Cardiology for the Primary Care Provider September 28, 201 Renovascular Hypertension

More information

University of Ulsan College of Medicine, Asan Medical Center on behalf of the REAL-LATE and the ZEST-LATE trial

University of Ulsan College of Medicine, Asan Medical Center on behalf of the REAL-LATE and the ZEST-LATE trial Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation A Pooled Analysis of the REAL-LATE and the ZEST-LATE Trial Seung-Jung Park MD PhD Seung-Jung Park, MD, PhD, University of Ulsan

More information

Rounds CARDIOLOGYTM. Percutaneous coronary intervention in the management of coronary artery disease. www.cardiologyrounds.ca.

Rounds CARDIOLOGYTM. Percutaneous coronary intervention in the management of coronary artery disease. www.cardiologyrounds.ca. Now Now available available on on the the Internet Internet www.cardiologyrounds.ca A U G U S T / S E P T E M B E R 2 0 0 1 volume VI, issue 7 CARDIOLOGYTM Rounds AS PRESENTED IN THE ROUNDS OF THE DIVISION

More information

Clinical Results of Unprotected Left Main Coronary Stenting

Clinical Results of Unprotected Left Main Coronary Stenting Original Articles IMAJ VOL 11 MARCH 2009 Clinical Results of Unprotected Left Main Coronary Stenting Itsik Ben-Dor MD, Hana Vaknin-Assa MD, Eli Lev MD, David Brosh MD, Shmuel Fuchs MD, Abid Assali MD and

More information

Payment policies are potentially a strong driver of diffusion of

Payment policies are potentially a strong driver of diffusion of Medical Devices Diffusion Of New Technology And Payment Policies: Coronary Stents The implementation of a higher payment rate for stenting did not drive the acceleration of the technology s diffusion,

More information

Coronary in-stent restenosis predictors, treatment and prevention

Coronary in-stent restenosis predictors, treatment and prevention European Heart Journal (2000) 21, 1739 1749 doi:10.1053/euhj.2000.2153, available online at http://www.idealibrary.com on Review Coronary in-stent restenosis predictors, treatment and prevention R. Hoffmann

More information

University of Missouri Kansas City School of Medicine and the Mid America Heart Institute of Saint Luke s Hospital

University of Missouri Kansas City School of Medicine and the Mid America Heart Institute of Saint Luke s Hospital PROGRAM DIRECTOR: Dr. Steven Laster University of Missouri Kansas City School of Medicine and the Mid America Heart Institute of Saint Luke s Hospital 1 Interventional Cardiology Fellowship Training Program

More information

TAXUS Express2 Paclitaxel-Eluting Coronary Stent System TAXUS Liberté Paclitaxel-Eluting Coronary Stent System. A Patient s Guide

TAXUS Express2 Paclitaxel-Eluting Coronary Stent System TAXUS Liberté Paclitaxel-Eluting Coronary Stent System. A Patient s Guide TAXUS Express2 Paclitaxel-Eluting Coronary Stent System TAXUS Liberté Paclitaxel-Eluting Coronary Stent System A Patient s Guide Table of Contents Coronary Artery Disease... 2 Who Is at Risk?... 3 Diagnosis

More information

SUTTER MEDICAL CENTER, SACRAMENTO Department of Cardiovascular Disease Cardiology - Delineation of Privileges

SUTTER MEDICAL CENTER, SACRAMENTO Department of Cardiovascular Disease Cardiology - Delineation of Privileges INITIAL: [ ] RENEWED: [ ] DATE: ADDITIONAL: [ ] Privileges are granted for Sutter General Hospital, Sutter Memorial Hospital, Sutter Center for Psychiatry, Sutter Oaks Midtown and the Capitol Pavilion

More information

CARDIAC RISKS OF NON CARDIAC SURGERY

CARDIAC RISKS OF NON CARDIAC SURGERY CARDIAC RISKS OF NON CARDIAC SURGERY N E W S T U D I E S & N E W G U I D E L I N E S W. B. C A L H O U N, M D, F A C C 2014 ACC/AHA Guideline on perioperative cardiovascular evaluation and management

More information

R EFERENCES. Summary and conclusions

R EFERENCES. Summary and conclusions R EFERENCES Summary and conclusions 129 S UMMARY AND CONCLUSIONS SUMMARY AND GENERAL DISCUSSION 130 Constant vasodilatation, inhibition of platelet and monocyte adhesion, and local thrombolysis are the

More information

Intracoronary stenting is an established treatment

Intracoronary stenting is an established treatment Indian Heart J 2001; 53: 275 281 Bahl et al. Elective Stenting in Small Coronary Arteries 275 Elective Stenting in Small Coronary Arteries: Lessons Learnt from Recent Trials Editorial VK Bahl, R Narang

More information

Clinical Commissioning Policy Statement: Percutaneous mitral valve leaflet repair for mitral regurgitation April 2013. Reference: NHSCB/A09/PS/b

Clinical Commissioning Policy Statement: Percutaneous mitral valve leaflet repair for mitral regurgitation April 2013. Reference: NHSCB/A09/PS/b Clinical Commissioning Policy Statement: Percutaneous mitral valve leaflet repair for mitral regurgitation April 2013 Reference: NHS Commissioning Board Clinical Commissioning Policy Statement: Percutaneous

More information

Validation of a Risk Score for Target Vessel Revascularization after Coronary Stent Implantation

Validation of a Risk Score for Target Vessel Revascularization after Coronary Stent Implantation Original Contribution Validation of a Risk Score for Target Vessel Revascularization after Coronary Stent Implantation a Alexandre S. Quadros, MD, PhD, b Fabiane Diemer, RN, b Dulce Welter, RN, Thais Modkowski,

More information

GRAFTMASTER RX Coronary Stent Graft System PPL2082232 (2/1/13)

GRAFTMASTER RX Coronary Stent Graft System PPL2082232 (2/1/13) GRAFTMASTER RX Coronary Stent Graft System PPL2082232 (2/1/13) Graphical Symbols for Medical Device Labeling Manufacturer Sterilized using ethylene oxide Catalogue number Batch code French size Outer diameter

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Coronary Stents. Artery Disease Review of Firs00t 1. Coronary Stents in the Management of

Coronary Stents. Artery Disease Review of Firs00t 1. Coronary Stents in the Management of Coronary Stents in the Management of Coronary Stents Artery Disease Review of Firs00t 1 S C Ng, FSCAP', Chen Sawatt, SRN, L K Foo, SRN, 0 Hitam, ASMLT, P G Khor, ASMLT, Y K Lee, ASMLT, *Ccmsuli:ant Interventional

More information

OPINION OPtical frequency domain imaging vs. INtravascular ultrasound in percutaneous coronary InterventiON

OPINION OPtical frequency domain imaging vs. INtravascular ultrasound in percutaneous coronary InterventiON OPINION OPtical frequency domain imaging vs. INtravascular ultrasound in percutaneous coronary InterventiON - Baseline preliminary results - Takashi Akasaka, MD, PhD, FESC Wakayama Medical University,

More information

6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology

6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology Objectives Acute Coronary Syndromes Epidemiology and Health Care Impact Pathophysiology Unstable Angina NSTEMI STEMI Clinical Clues Pre-hospital Spokane County EMS Epidemiology About 600,000 people die

More information

2014 Procedural Reimbursement Guide Select Percutaneous Coronary Interventions

2014 Procedural Reimbursement Guide Select Percutaneous Coronary Interventions 2014 Procedural Reimbursement Guide Select Percutaneous Coronary Interventions IC-221010-AA Jan 2014 Page 1 of 10 Interventional Cardiology This for interventional cardiology procedures provides coding

More information

Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care

Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

More information

Christopher M. Wright, MD, MBA Pioneer Cardiovascular Consultants Tempe, Arizona

Christopher M. Wright, MD, MBA Pioneer Cardiovascular Consultants Tempe, Arizona Christopher M. Wright, MD, MBA Pioneer Cardiovascular Consultants Tempe, Arizona Areas to be covered Historical, current, and future treatments for various cardiovascular disease: Atherosclerosis (Coronary

More information

2015 European Coronary Stent New Product Innovation Award

2015 European Coronary Stent New Product Innovation Award 2015 European Coronary Stent New Product Innovation Award 2015 Contents Background and Company Performance... 3 Industry Challenges... 3 New Product Attributes and Customer Impact... 3 Conclusion... 4

More information

Carotid Artery Stenting? Comparison of the outcome of octogenarian patients according to the stent type. Data from a multicentre registry

Carotid Artery Stenting? Comparison of the outcome of octogenarian patients according to the stent type. Data from a multicentre registry Closed- or Open-cell stents in Carotid Artery Stenting? Comparison of the outcome of octogenarian patients according to the stent type. Data from a multicentre registry Nikas D 1, Reimers B 2, Iakovou

More information

Understanding Coronary Artery Disease, Cardiac Catheterization, and Treatment Options. A Guide for Patients

Understanding Coronary Artery Disease, Cardiac Catheterization, and Treatment Options. A Guide for Patients Understanding Coronary Artery Disease, Cardiac Catheterization, and Treatment Options A Guide for Patients Coronary Artery Disease If you or a member of your family has been diagnosed with coronary artery

More information

Ischemia and Infarction

Ischemia and Infarction Harvard-MIT Division of Health Sciences and Technology HST.035: Principle and Practice of Human Pathology Dr. Badizadegan Ischemia and Infarction HST.035 Spring 2003 In the US: ~50% of deaths are due to

More information

OCT STEMI: OCT guidance during stent implantation

OCT STEMI: OCT guidance during stent implantation OCT STEMI: OCT guidance during stent implantation in primary PCI. A Randomized Multicenter study with 9-month optical coherence tomography follow-up Červinka P 1,2, Kala P 3, Jakl M 2,4, Kaňovský J 3,

More information

Review Article CORONARY STENTS - PAST, PRESENT AND FUTURE.

Review Article CORONARY STENTS - PAST, PRESENT AND FUTURE. Review Article CORONARY STENTS - PAST, PRESENT AND FUTURE. VV JAIN*, S YELWATKAR**, OP GUPTA*** Introduction The advent of period of angioplasty has revolutionized the practice of interventional cardiology.

More information

First Experience With Drug-Eluting Balloons in Infrapopliteal Arteries

First Experience With Drug-Eluting Balloons in Infrapopliteal Arteries Journal of the American College of Cardiology Vol. 58, No. 11, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.05.034

More information

Wingspan Stent System with Gateway PTA Balloon Catheter

Wingspan Stent System with Gateway PTA Balloon Catheter Wingspan System with Gateway PTA Balloon Catheter Directions for Use AUS Australian Sponsor Address Boston Scientific (Australia) Pty Ltd PO Box 332 BOTANY NSW 1455 Australia Free Phone 1800 676 133 Free

More information

Ultrasound in Vascular Surgery. Torbjørn Dahl

Ultrasound in Vascular Surgery. Torbjørn Dahl Ultrasound in Vascular Surgery Torbjørn Dahl 1 The field of vascular surgery Veins dilatation and obstruction (varicose veins and valve dysfunction) Arteries dilatation and narrowing (aneurysms and atherosclerosis)

More information

Intravascular Diagnostic Procedures and Imaging Techniques Versus Angiography Alone in Coronary Stenting: Future Research Needs

Intravascular Diagnostic Procedures and Imaging Techniques Versus Angiography Alone in Coronary Stenting: Future Research Needs Future Research Needs Paper Number 25 Intravascular Diagnostic Procedures and Imaging Techniques Versus Angiography Alone in Coronary Stenting: Future Research Needs Future Research Needs Paper Number

More information

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38 Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac

More information

Cardiovascular disease has become a dominant cause of

Cardiovascular disease has become a dominant cause of Abstract Immediate and Six-month Clinical Outcome of Percutaneous Coronary Intervention in a Tertiary Hospital in the Sultanate of Oman Panduranga Prashanth, Mohamed Mukhaini, Abdulla A. Riyami, Kadhim

More information

FFR CT : Clinical studies

FFR CT : Clinical studies FFR CT : Clinical studies Bjarne Nørgaard Department Cardiology B Aarhus University Hospital Skejby, Denmark Disclosures: Research grants: Edwards and Siemens Coronary CTA: High diagnostic sensitivity

More information

Everolimus Eluting Coronary Stent System. Patient Information Guide

Everolimus Eluting Coronary Stent System. Patient Information Guide Everolimus Eluting Coronary Stent System Patient Information Guide Table of Contents Coronary Artery Disease (CAD)...5 Your Heart...5 What is CAD?...5 What are the Symptoms of CAD?...5 What are the Risk

More information

High incidence of thrombus formation at 18 months after paclitaxel-eluting stent implantation: Angioscopic comparison with sirolimus-eluting stent

High incidence of thrombus formation at 18 months after paclitaxel-eluting stent implantation: Angioscopic comparison with sirolimus-eluting stent High incidence of thrombus formation at 18 months after paclitaxel-eluting stent implantation: Angioscopic comparison with sirolimus-eluting stent Masahiko Hara, MD, Masami Nishino, MD, Masayuki Taniike,

More information

REPORTING STENT PLACEMENT FOR NONOCCLUSIVE VASCULAR DISEASE IN LOWER EXTREMITIES

REPORTING STENT PLACEMENT FOR NONOCCLUSIVE VASCULAR DISEASE IN LOWER EXTREMITIES REPORTING STENT PLACEMENT FOR NONOCCLUSIVE VASCULAR DISEASE IN LOWER EXTREMITIES Effective January 1, 2015, there was a change in CPT that affects reporting specific endovascular services provided in the

More information

Drug-Eluding Stents as an Alternative to Traditional Stenting in the Treatment of Coronary Artery Disease

Drug-Eluding Stents as an Alternative to Traditional Stenting in the Treatment of Coronary Artery Disease TITLE: Drug-Eluding Stents as an Alternative to Traditional Stenting in the Treatment of Coronary Artery Disease AUTHOR: Mitchell D. Feldman, MD, M.Phil. Professor of Medicine Division of General Internal

More information

Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg

Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg 2 nd Annual Duke Renal Transplant Symposium March 1, 2014 Durham, NC Joseph G. Rogers, M.D. Associate

More information

INVESTIGATION OF METALLIC SURFACE AREA OF CORONARY STENTS

INVESTIGATION OF METALLIC SURFACE AREA OF CORONARY STENTS INVESTIGATION OF METALLIC SURFACE AREA OF CORONARY STENTS Dóra Károly 1, Miksa Kovács 1, Andrew Attila Terdik 1, Eszter Bognár 1,2 1Department of Materials Science and Engineering, Faculty of Mechanical

More information

ST. DAVID S MEDICAL CENTER CARDIOLOGY - Special, Invasive, Diagnostic, or High-Risk Procedure Requirements

ST. DAVID S MEDICAL CENTER CARDIOLOGY - Special, Invasive, Diagnostic, or High-Risk Procedure Requirements ST. DAVID S MEDICAL CENTER CARDIOLOGY - Special, Invasive, Diagnostic, or High-Risk Procedure Requirements Cardiac Catheterization & Peripheral Angiography Completion of a fellowship in Cardiovascular

More information